AUTL - Why Autolus Therapeutics Stock Skyrocketed Today
Shares of Autolus Therapeutics (NASDAQ: AUTL) were trading 35% higher as of 3:37 p.m. EDT on Wednesday. Those big gains came after the company announced that its experimental CD19 cell therapy, AUTO1, had achieved 100% remission in patients with relapsed/refractory indolent non-Hodgkin lymphoma in an early-stage study.
Autolus stated that AUTO1's results will be included in an abstract presentation at the European Hematology Association (EHA) Virtual Congress scheduled for June 9 through June 17. The company said that of the 10 patients who had received AUTO1 as of Feb. 18, nine were evaluable. All nine of those patients achieved complete remission rates.
Image source: Getty Images.
For further details see:
Why Autolus Therapeutics Stock Skyrocketed Today